CORVUS PHARMACEUTICALS INC

NASDAQ: CRVS (Corvus Pharmaceuticals, Inc.)

Kemas kini terakhir: semalam, 11:19AM

10.43

-0.17 (-1.60%)

Penutupan Terdahulu 10.60
Jumlah Dagangan 377,116
Harga / Buku (P/B) 4.31
Julat 52 Minggu
6.39 (-38%) — 26.95 (158%)
EPS Cair (TTM) -1.03
Jumlah Hutang/Ekuiti (D/E MRQ) 2.34%
Nisbah Semasa (MRQ) 4.90
Aliran Tunai Operasi (OCF TTM) -28.53 M
Aliran Tunai Bebas Leveraj (LFCF TTM) -13.17 M
Pulangan Atas Aset (ROA TTM) -39.21%
Pulangan Atas Ekuiti (ROE TTM) -100.13%

AISkor Stockmoo

-2.7
Daripada penilaian laporan AI Insight kami tentang pulangan dijangka berbanding risiko. info NA
Penilaian Relatif info NA
Pertumbuhan Tersirat info NA
Sejarah Penilaian info NA
Hutang rendah. Keuntungan lemah. Kecairan jangka pendek mencukupi. Aliran tunai negatif. info
Pulangan di bawah kos modalnya. Pulangan atas modal menurun. info
Daripada analisis teknikal AI kami terhadap carta. info NA
Tiada aliran jelas sepanjang tahun lalu. Jauh di bawah paras tertinggi 52 minggu. info
Harga dan purata bergeraknya tersusun dalam aliran menurun. Purata bergerak utamanya sedang menurun. Hampir dengan purata bergerak yang menurun. Di bawah purata bergerak jangka panjang, jadi tidak dinilai positif. info
Corak pembalikan menurun baru-baru ini: Engulfing menurun. info
Di bawah garis aliran jangka sederhana. info
Tiada harga sasaran terkini, jadi berdasarkan arah semakan harga sasaran. info
Berita terkini bercampur atau neutral. info
Orang dalam membeli bersih baru-baru ini. Harga di bawah harga belian orang dalam. info
Institusi bersih -1.83% daripada saham dalam pemfailan 13F terkini: 88 pemegang menambah, 79 mengurang (suku berakhir 30 Sep 2026). info
Kedudukan jual singkat -6.6% dari 31 Aug hingga 30 Oct 2026, 18.8 hari untuk tutup (FINRA). info
Persekitaran pasaran berhati-hati. info
Sektor ketinggalan berbanding pasaran.
Tonggak-tonggak sependapat, jadi skor diperkukuh.
Harga rendah berbanding purata 52 minggunya. Naik dalam tempoh 5 tahun. info
Momentum jangka pendek meningkat. info
Harga di antara sokongan dan rintangan. info
Skor Akhir -2.70
Tunjuk semua

Arah Aliran Pasaran

Jangka Pendek Jangka Sederhana
Industri Biotechnology (US) Bercampur Menaik
Biotechnology (Global) Bercampur Menaik
Stok Corvus Pharmaceuticals, Inc. Bercampur Menaik

Saham Serupa

Stok Modal Pasaran DY P/E (TTM) P/B
CRVS - - - 4.31
TRML 1 B - - 4.76
CTMX - - - 1.56
GANX - - - 4.54
SRRK - - - 31.23
IRON - - - 5.11

Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. It believes its proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The company operates in one primary business activity and operate as one reportable segment.

Sektor Healthcare
Industri Biotechnology
Gaya Pelaburan Small Core
% Dimiliki oleh Orang Dalam 3.83%
% Dimiliki oleh Institusi 48.27%

Pemilikan

Nama Tarikh Syer Dipegang
Adams Street Partners Llc 30 Sep 2026 3,275,616
Deep Track Capital, Lp 30 Sep 2026 2,491,939
Foresite Capital Management Vi Llc 30 Sep 2026 1,831,233

Tiada data dalam julat masa ini.

Nama Purata Belian ($) Purata Jualan ($) Jumlah Net Jumlah Nilai Bersih ($)
ARCARA JEFFREY 11.19 - 4,500 50,360
Jumlah Keseluruhan Kuantiti Bersih 4,500
Jumlah Keseluruhan Nilai Bersih ($) 50,360
Purata Pembelian Keseluruhan ($) 11.19
Purata Jualan Keseluruhan ($) -
Nama Pemegang Tarikh Jenis Kuantiti Harga Nilai ($)
ARCARA JEFFREY Pegawai 13 Nov 2026 Beli (+) 1,003 10.64 10,672
ARCARA JEFFREY Pegawai 12 Nov 2026 Beli (+) 497 10.62 5,278
ARCARA JEFFREY Pegawai 11 Nov 2026 Beli (+) 3,000 11.47 34,410

Institusi

Pemilikan institusi: 86.31%

Kedudukan Pemegang Saham
Bertambah 88 6,554,089
Berkurang 79 8,031,042
Baharu 29 2,064,545
Dijual habis 18 2,124,893

Pemfailan SEC 13F melalui Nasdaq, pemfailan terkini hingga 30 Sep 2026. Pemfailan tiba sehingga 45 hari selepas setiap suku.

Kedudukan Jual Singkat

Penyelesaian Saham Hari untuk tutup
30 Oct 2026 17,759,451 18.8
15 Oct 2026 17,967,756 14.9
30 Sep 2026 17,797,751 13.3
15 Sep 2026 17,180,341 18.2
31 Aug 2026 19,017,840 29.6
14 Aug 2026 19,127,098 22.5

Data jual singkat FINRA melalui Nasdaq, dilaporkan dua kali sebulan.

1 Positif 1 Negatif 6 Neutral
Tarikh Jenis Butiran
09 Nov 2026 Yahoo Finance Corvus Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference in London
SOUTH SAN FRANCISCO, Calif., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced that members of its leadership team will conduct one-on-one meetings with investors and present a corporate overview at the 2026…
06 Nov 2026 Yahoo Finance Corvus (CRVS) Q3 2026 Earnings Call Transcript
Soquelitinib's expanding pipeline spans lymphoma, eczema, skin disease and asthma.
06 Nov 2026 Yahoo Finance Corvus Pharmaceuticals Inc (CRVS) Q3 2026 Earnings Call Highlights: Strong Cash Runway and Key ...
Corvus Pharmaceuticals Inc (CRVS) reported a $20.3 million net loss but holds $202.9 million in cash to fund operations into Q2 2028, with pivotal socolitinib data readouts expected through 2027…
06 Nov 2026 Yahoo Finance Corvus Pharmaceuticals, Inc. Q3 2026 Earnings Call Summary
Moby summary of Corvus Pharmaceuticals, Inc.'s Q3 2026 earnings call…
05 Nov 2026 Yahoo Finance What Corvus Pharmaceuticals (CRVS) Said on Its Q3 Earnings Call
Corvus Pharmaceuticals (NASDAQ:CRVS) reported a wider third-quarter loss as spending on clinical trials increased, while executives outlined a series of 2027 milestones for its lead experimental drug, soquelitinib. The company reported a net loss of $20.3 million for the third quarter of 2026, comp…
05 Nov 2026 Yahoo Finance Corvus: Q3 Earnings Snapshot
(AP) — SOUTH SAN FRANCISCO, Calif. (AP) — Corvus Pharmaceuticals Inc.
05 Nov 2026 Yahoo Finance Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2026 Financial Results
Enrollment in soquelitinib registrational Phase 3 relapsed/refractory peripheral T-cell lymphoma (PTCL) and Phase 2 atopic dermatitis trials on track Angel Pharmaceuticals completes enrollment in cohort 1 of Phase 1b/2 atopic dermatitis trial; topline data anticipated in March 2027 Phase 1b…
04 Nov 2026 Yahoo Finance Corvus Pharmaceuticals Announces Initial Data from Soquelitinib Clinical Trial in Patients with Autoimmune Lymphoproliferative Syndrome (ALPS) will be Presented at the 68ᵗʰ American Society for Hematology Annual Meeting & Exposition
Data shows positive one-year safety and efficacy data from three patients enrolled in ongoing Phase 2 clinical trial being led by researchers at the National Institute of Allergy and Infectious Diseases (NIAID) Safety profile consistent with results from soquelitinib T cell lymphoma and atopic…
29 Oct 2026 Yahoo Finance Corvus Pharmaceuticals to Provide Business Update and Third Quarter 2026 Financial Results on November 5, 2026
Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PTSOUTH SAN FRANCISCO, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced that the company will host a conference call and webcast on…
30 Sep 2026 Yahoo Finance Corvus Pharmaceuticals Announces Initiation of Phase 1b Clinical Trial of Soquelitinib for Patients with Hidradenitis Suppurativa
Clinical trial designed to demonstrate proof-of-concept for soquelitinib in the treatment of hidradenitis suppurativa and evaluate its effects on Th17 biologySOUTH SAN FRANCISCO, Calif., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage…
25 Sep 2026 Yahoo Finance Corvus Pharmaceuticals (CRVS) Faces A Valuation Test, Is The Upside Already Priced In?
Corvus Pharmaceuticals (CRVS) has drawn fresh attention after recent trading left the biotech down about 19% over the past month and 13% over the past 3 months from a US$11.80 close. That recent slide sits against a much stronger ride for Corvus Pharmaceuticals, with the share price return still up…
03 Sep 2026 Yahoo Finance Corvus Pharmaceuticals to Present at the 2026 Cantor Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that members of its leadership team will conduct one-on-one meetings with investors and participate in a fireside chat…
27 Aug 2026 Yahoo Finance Corvus Pharmaceuticals Announces Publication in Blood of Final Phase 1 Data from the Soquelitinib Phase 1/1b T Cell Lymphoma Trial
Data supports ongoing registration Phase 3 trial in r/r PTCL, Phase 2 trial in atopic dermatitis and planned trials for hidradenitis suppurativa and asthma Data in T cell lymphoma demonstrated anti-tumor activity based on tumor intrinsic and tumor extrinsic effects on microenvironment Highlights…
Papar semua

Isyarat Terkini corak lilin dan silang EMA

▼ Engulfing menurun Jangka pendek · Harian · 1 sesi lalu · 16 Nov
Badan lilin turun menutup sepenuhnya lilin naik sebelumnya, selepas kenaikan. Isyarat pembalikan menurun.

Persediaan Teknikal Sederhana

Susunan aliran
Kecerunan
Kemasukan
Dagangan
Harga dan purata bergeraknya tersusun dalam aliran menurun. Purata bergerak utamanya sedang menurun. Hampir dengan purata bergerak yang menurun. Di bawah purata bergerak jangka panjang, jadi tidak dinilai positif.
Sokongan terdekat: 9.41 – 9.99 · paras kukuh
Rintangan terdekat: 10.51 – 11.00 · paras kukuh

AI Analisis Teknikal

Portfolio

AI Templat

Peringatan harga anda

Profil Risiko

| | | | |
Konservatif
Sederhana Konservatif
Sederhana
Sederhana Agresif
Agresif
Margin Keselamatan (EP)
Keuntungan Separa (TP1)
Keuntungan Sasaran (TP2)
Kerugian Maksimum (SL)

Penafian: Perkara di atas adalah untuk tujuan ilustrasi sahaja dan BUKAN nasihat pelaburan. Dapatkan nasihat daripada penasihat kewangan yang berkelayakan.

Harga Masuk (EP)

Ambil Untung 1 (TP1)

Ambil Untung 2 (TP2)

Henti Rugi (SL)

Julat 52 Minggu
 
52WL
 
52WH
SL
EP
TP1
TP2

Semua harga peringatan berada dalam julat harga 52 minggu

Keuntungan Nyata -
Keuntungan Tidak Nyata -
Dividen Diterima 2026 -
Jumlah Untung -
Pulangan Purata -
Kuantiti (Beli) -
Purata Harga (Beli) -
Kuantiti (Jual) -
Purata Harga (Jual) -
Tiada saham yang memenuhi kriteria anda